NASH: regulatory considerations for clinical drug development and U.S. FDA approval
Crossref DOI link: https://doi.org/10.1038/s41401-021-00832-z
Published Online: 2022-01-21
Published Print: 2022-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Harvey, Brian E.
Text and Data Mining valid from 2022-01-21
Version of Record valid from 2022-01-21
Article History
Received: 1 September 2021
Accepted: 23 November 2021
First Online: 21 January 2022
Competing interests
: The author declares no competing interests.